Articles tagged with Stomach Neoplasms
A study published in the Journal of the American College of Surgeons found that laparoscopic removal of gastrointestinal stromal tumors (GISTs) is safe and effective. The disease-free survival rate for patients who underwent laparoscopic treatment was nearly 80% after an average follow-up time of three and a half years.
Researchers at the University of Toronto have discovered that the EBNA1 protein of Epstein-Barr virus disrupts structures in nasopharyngeal carcinoma cells, interfering with cellular processes that prevent cancer development. The study provides a novel mechanism by which viral proteins contribute to carcinogenesis.
Researchers found that reduced expressions of E-cadherin and P120 were associated with tumor grade and patient survival in cholangiocarcinoma. These biomarkers may serve as potential diagnostic and prognostic indicators for ICCs.
The IL-11 protein is identified as the primary driver of tumor development in the stomach, promoting chronic inflammation and tumorigenesis by inducing excessive activation of Stat3. Inhibiting this signaling pathway prevents or reduces tumorigenesis in a mouse model of gastric cancer, offering hope for the development of new treatments.
A rare pancreatic tumor was treated with surgery and chemotherapy, resulting in long-term stability. The case report reviews the impact of aggressive surgery on prognosis.
Researchers used FDG PET/CT to monitor early responses and found that combining EGFR-specific antibodies with VEGF-specific antibodies may improve anti-tumor efficacy. The novel approach also shows potential for anticancer therapy by monitoring molecular treatment responses.
A large sample size study found endoscopic resection to be a safe and effective treatment for gastrointestinal smooth muscle tumors (SMTs) with base sizes ≤ 2 cm. No severe complications or recurrences were observed in cases treated using the 'pushing' or 'grasping and pushing' technique.
Italian scientists have discovered a new target for anti-tumor therapy in cancer, finding that the Trop-2 gene is expressed in the vast majority of human cancers. The gene's over-expression was found in between 65% and 90% of tumor types analyzed.
A phase II trial found that six of 17 patients with metastatic colorectal cancer showed significant tumor shrinkage after receiving the therapeutic vaccine TroVax. The study demonstrated the safety and immunogenicity of the vaccine, suggesting its potential as an immuno-therapy approach to enhance the immune response to tumors.
Researchers found that approximately 97% of patients who received imatinib after surgery did not experience cancer recurrence, compared to 83% of those who received placebo. Gleevec was well-tolerated by most patients and showed significant benefits in decreasing cancer recurrence.
Scientists have found a way to activate EBV inside tumors, allowing them to identify patients whose infection can be manipulated to destroy their tumors. The technique uses two agents already on the market to light up tumor viruses, offering a novel approach to treating cancers associated with Epstein-Barr.
A study led by Michael C. Heinrich, M.D., found that patients with gastrointestinal stromal tumor (GIST) responded differently to Sunitinib depending on their tumor's genetic abnormality. The research highlights the importance of personalized medicine in cancer treatment.
A study published in Nature Genetics found that precancerous tumors with diverse cell populations are more likely to evolve into cancer. The research suggests that genetic diversity could serve as a biomarker for cancer risk, and may help doctors assess the success of cancer prevention therapies.
Researchers have created a new model to examine the process by which tumor cells develop an angiogenic phenotype, enabling them to grow rapidly. The study found that non-angiogenic tumor cells can switch to angiogenesis after several months, and that this switch is crucial for tumor growth and metastasis.
Researchers found that antibiotics are less effective in preventing recurrent gastric lymphoma when H. pylori is re-infected, and that follicular dendritic cells play a key role in the disease's progression. Re-infected animals developed more aggressive tumors than those who received antibiotic treatment.
Researchers found that patients with Barrett mucosa had tumors diagnosed earlier, were smaller in size, and had a better five-year survival rate. Conversely, adenocarcinomas without detectable Barrett epithelium may be more advanced stages of the same disease, leading to poorer outcomes.
Researchers analyzed tumor DNA from 324 GIST patients and found that those with a KIT exon 11 mutation responded better to Gleevec. The study confirms the need for new drugs for patients whose GIST genotype is less responsive to Gleevec.
A study published in Genes and Development reveals a novel molecular player influencing colon cancer initiation. The research found that combining Foxl1 deficiency with an inactive APC gene accelerated tumor formation, highlighting the significance of mesenchymal-epithelial signaling in gastrointestinal tumorigenesis.
A recent study found that ethanol exposure increases tumor size, blood vessel density, and VEGF levels in chick embryos, supporting the hypothesis that ethanol-induced angiogenesis contributes to cancer progression. The study provides new insights into the mechanisms underlying alcohol's association with various types of cancer.
Using MRI guidance, doctors can target and freeze liver tumors with cryotherapy, achieving high success rates and minimal scarring. The non-invasive procedure results in quicker recovery times and shorter hospital stays.
The study used wireless capsule endoscopy to detect 73 small bowel tumors, including 65% that were malignant. Capsule endoscopy provides a new option for diagnosing small bowel tumors, previously difficult to access through traditional endoscopic methods.
A study published in PLOS Biology discovered a common genetic signature linked to the progression of various cancers, including prostate and liver cell carcinomas. Patients with tumors carrying this signature had an increased risk of metastasis and death compared to those without it.
Scientists have developed a method that uses allicin, found in garlic, to selectively kill cancer cells in mice. The method involves injecting an antibody and enzyme combination that targets specific receptors on cancer cells, triggering the production of lethal allicin molecules that destroy tumors while leaving healthy cells intact.
Researchers analyzed DNA samples from 127 patients with gastrointestinal stromal tumors (GISTs) to determine if a KIT tyrosine kinase mutation was present and its impact on Gleevec response. Patients with favorable lab results had an 84 percent chance of partial remission, while those with unfavorable results did not respond.
Researchers found that Hedgehog's signal is required for cancer growth in the digestive tract. A plant-derived chemical called cyclopamine blocked this signal, killing tumors in mice without harm.
Researchers are developing a nanoprobe for early cancer diagnosis using optical coherence tomography, potentially replacing traditional biopsies. The probe aims to pinpoint microscopic changes in tissue structure and blood flow with high-speed, high-resolution imaging.
Imatinib mesylate has shown significant effectiveness in treating gastrointestinal stromal tumours (GISTs), a previously difficult-to-treat cancer type. The drug's success is attributed to its ability to target KIT tyrosine kinase mutations, which are present in most GISTs.